Publication details

c-MET-mediated resistance to EGFR inhibitors in head and neck cancer: How to move from bench to bedside

Authors

SZTURZ Petr RAYMOND E. FAIVRE S.

Year of publication 2016
Type Article in Periodical
Magazine / Source Oral oncology
MU Faculty or unit

Faculty of Medicine

Citation
Web http://www.sciencedirect.com/science/article/pii/S136883751630063X
Doi http://dx.doi.org/10.1016/j.oraloncology.2016.05.017
Field Oncology and hematology
Keywords squamous-cell carcinoma; randomized phase-ii; tivantinib arq 197; lung-cancer; acquired-resistance; metastatic head; plus erlotinib; double-blind; patients pts; placebo
Description Mesenchymal–epithelial transition factor (c-MET), found on melanocytes, endothelial cells, and epithelial tissues, is a membrane spanning receptor tyrosine kinase for hepatocyte growth factor (HGF), produced by elements of mesenchymal origin. The receptor-ligand pair controls diverse biological activities including cell proliferation, motility, invasiveness, morphogenesis, apoptosis, and angiogenesis.

You are running an old browser version. We recommend updating your browser to its latest version.

More info